PRHUB has announced three wins in the healthcare & biosciences space – Medall Diagnostics, India’s 4^th largest diagnostics chain serving 9 million customers, Transasia Bio-Medicals, an in-vitro diagnostic company and Singapore-based Aum Biosciences, an oncology-focused biotech venture for affordable oncology therapeutics.

 The mandates include brand consulting and social media marketing alongside the media. The Singapore win is the first time PRHUB will service a client based out of Singapore.

Explaining the rationale for engaging with PRHUB, Vishal Doshi, founder & CEO, AUM Biosciences, said,” We are a unique venture that is seeking to transform how niche oncology therapeutic innovation are developed from Asia to go global. A complex business model in a niche area and a global impact, meant you need a partner who navigates multiple elements well.”

 Raju Venkatraman, founder & CEO, Medall Healthcare Pvt. Ltd., said,” We were seeking a partner who brought a clear understanding of the unique situation we are in, fresh strategic clarity on how to use communication to solve certain challenges and the expertise to deliver. PRHUB did well on all these parameters.”

According to Suresh Vazirani, chairman & managing director, Transasia Bio-Medicals Ltd.,” We were quite finicky about our choice of a PR partner and it was for the exact reason we waited for 2 long years almost before finalizing on PRHUB. They understood our business & needs quickly, were flexible to our exacting requirements and demonstrated their execution capability as well with the first-ever press conference we did recently.”